MTVA

MetaVia Inc. (NASDAQ:MTVA) is a clinical-stage biotechnology company founded in 2016 and headquartered in Cambridge, Massachusetts. The company was formerly known as NeuroBo Pharmaceuticals, Inc. until changing its name to MetaVia Inc. in November 2024. MetaVia focuses on developing novel pharmaceutical treatments for cardiometabolic diseases, which encompass conditions affecting both cardiovascular health and metabolic processes such as diabetes, obesity, and liver disease. The company operates as a development-stage biopharmaceutical firm with multiple drug candidates in various phases of clinical trials, but has not yet generated commercial revenue from product sales.